TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
October 18, 2022 10:07 ET
|
TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress
September 10, 2022 12:30 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 10, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced today initial results from a Phase 0 clinical trial of pamiparib in...
Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care
September 07, 2022 09:00 ET
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA)
September 06, 2022 07:59 ET
|
Ocean Biomedical, Inc.
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”....
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
September 06, 2022 07:45 ET
|
Aesther Healthcare Acquisition Corp.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol,...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
July 26, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
Ivy Brain Tumor Center at Barrow Neurological Institute Launches Spanish-Language Website
June 15, 2022 09:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, June 15, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit early-phase drug development program for brain cancer, has announced the...
Brain Cancer Canada funds Canada's first genomics technology for rapid and precise brain tumour diagnostics
May 01, 2022 09:00 ET
|
Brain Cancer Canada
TORONTO, May 01, 2022 (GLOBE NEWSWIRE) -- Today marks the first day of Brain Cancer Awareness month. On this day Brain Cancer Canada grants $100,000 to the St. Michael's Hospital program to acquire...
Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas
March 16, 2022 10:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, March 16, 2022 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced the opening...
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
December 21, 2021 19:49 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with...